share_log

Wells Fargo Maintains Overweight on Ventyx Biosciences, Lowers Price Target to $11

Benzinga ·  Aug 13 01:48  · Ratings

Wells Fargo analyst Derek Archila maintains Ventyx Biosciences (NASDAQ:VTYX) with a Overweight and lowers the price target from $16 to $11.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment